Novo Holdings Amends Edgewise Therapeutics Stake

TL;DR

Novo Holdings filed an update on their Edgewise Therapeutics holdings. Keep an eye on this.

AI Summary

Novo Holdings A/S, through its filing on September 23, 2024, has amended its Schedule 13D regarding Edgewise Therapeutics, Inc. This amendment, designated as Amendment No. 5, indicates a change in the reporting of beneficial ownership. Novo Holdings A/S is a significant investor in the pharmaceutical preparations sector.

Why It Matters

This filing signals a potential shift in the ownership structure or investment strategy of Novo Holdings A/S concerning Edgewise Therapeutics, which could impact the company's future direction.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings often indicate changes in significant beneficial ownership, which can lead to increased volatility or strategic shifts for the subject company.

Key Players & Entities

• Novo Holdings A/S (company) — Filing entity
• Edgewise Therapeutics, Inc. (company) — Subject company
• Barbara Fiorini (person) — Person authorized to receive notices
• B. Shayne Kennedy (person) — Copy to contact
• Latham & Watkins LLP (company) — Legal counsel

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $29.13 — ovo Holdings A/S sold 575,900 shares at $29.13 per share in the open market. On Sept
• $28.58 — ovo Holdings A/S sold 218,630 shares at $28.58 per share in the open market. Item5.

Filing Documents

• d894517dsc13da.htm (SC 13D/A) — 65KB
• 0001193125-24-223906.txt ( ) — 66KB

is amended and replaced in its entirety as follows

Item 2 is amended and replaced in its entirety as follows: (a) Novo Holdings A/S, a Danish corporation, is an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation (the Foundation ), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies (currently comprised of Novo Nordisk A/S and Novozymes A/S) and is responsible for managing the Foundations assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S. The name of each director and executive officer of both Novo Holdings A/S and the Foundation is set forth on the updated Schedule I to this Amendment No. 5. (b) The business address of both Novo Holdings A/S and the Foundation is Tuborg Havnevej 19, 2900 Hellerup, Denmark. The residence or business address of each director and executive officer of both Novo Holdings A/S and the Foundation is set forth on the updated Schedule I to this Schedule 13D. (c) Novo Holdings A/S, a holding company that is responsible for managing the Foundations assets, provides seed and venture capital to development stage companies and invests in well-established companies within the life science and biotechnology sector. The Foundation is a Danish self-governing and profit-making foundation, whose objectives are to provide a stable basis for commercial and research activities undertaken by the group of Novo companies and to support scientific, humanitarian and social purposes through grants. (d) Within the last five years, neither Novo Holdings A/S, the Foundation, nor any person named in the updated Schedule I has been convicted in any criminal proceedings. (e) Within the last five years, neither Novo Holdings A/S, the Foundation, nor any person named in the updated Schedule I was a party to a civil pr

is amended and replaced in its entirety as follows

Item 5 is amended and replaced in its entirety as follows: 3 (a) Novo Holdings A/S beneficially owns 5,549,900 shares of Common Stock (the Novo Shares ) representing approximately 5.9% of the Issuers outstanding shares of Common Stock, based upon 93,772,288 shares of the Issuers Common Stock outstanding as of July 31, 2024, as reported in the Issuers Form 10-Q filed with the SEC on August 8, 2024. (b) Novo Holdings A/S is a Danish corporation wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on the updated Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares. (c) Except as described herein, Novo Holdings A/S has not effected any transactions in the Issuers Common Shares within the past 60 days and neither the Foundation nor any person listed on the updated Schedule I has effected any transactions in the Issuers Common Shares within the past 60 days. (d) Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Novo Shares. (e) Not applicable. 4 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: September 23, 2024 Novo Holdings A/S /s/ Barbara Fiorini Due By: Barbara Fiorini Due Its: General Counsel, Finance & Operations Schedule I Information regarding each director and executive officer of both Novo Holdings A/S and the Novo Nordisk Foundation is set forth below. Novo Holdings A/S Name, Title Address Principal Occupation Citizenship Lars Rebien Sørensen, Chair of the Board Via Volpini, 35 53040 Cetona SI, Italy Professional Board Director Denmark Steen Riisgaard, Vice Chair of the Board Hestetangsvej 155, 3520

View Full Filing

View this SC 13D/A filing on SEC EDGAR